HR Positive
Showing 1 - 25 of >10,000
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;
Recruiting
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Hangzhou, Zhejiang, ChinazhejiangCH
Nov 9, 2023
HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)
Not yet recruiting
- HER2 Low Breast Carcinoma
- SHR-A1811 for injection
- (no location specified)
Jun 12, 2023
Breast Cancer Trial in Tianjin (Dalcelli?Exemestane?Gosserine, Docetaxel for injection?Epirubicin HCl for
Recruiting
- Breast Cancer
- Dalcelli、Exemestane、Gosserine
- Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection
-
Tianjin, Tianjin, ChinaJie Ge
Aug 20, 2023
Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)
Not yet recruiting
- Breast Cancer
- Dalpiciclib combined with Letrozole
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Aug 3, 2023
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,
Not yet recruiting
- Breast Cancer Invasive
- +3 more
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023
Breast Cancer Trial in Shanghai (Dalpiciclib, Fulvestrant, Pertuzumab)
Active, not recruiting
- Breast Cancer
- Dalpiciclib
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Oct 10, 2022
Breast Tumor Female Trial in Beijing (CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou))
Recruiting
- Breast Neoplasm Female
- CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
-
Beijing, Beijing, China
- +1 more
Jul 31, 2023
HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)
Recruiting
- HR Positive HER2 Negative Advanced Breast Cancer
-
Tianjin, China天津市肿瘤医院
May 26, 2023
Breast Cancer Trial in Nanjing (Neoadjuvant therapy: TCbHPy, Neoadjuvant therapy: TCbHP)
Not yet recruiting
- Breast Cancer
- Neoadjuvant therapy: TCbHPy
- Neoadjuvant therapy: TCbHP
-
Nanjing, Chinathe First Affiliated Hospital of Nanjing Medical University
Jul 4, 2022
Advanced Breast Cancer Trial in Thalassery (Alpelisib, Fulvestrant)
Recruiting
- Advanced Breast Cancer
-
Thalassery, Kerala, IndiaNovartis Investigative Site
Nov 21, 2022
Breast Cancer Trial in Zhengzhou (Capecitabine+endocrine therapy, Placebo+endocrine therapy)
Recruiting
- Breast Cancer
- Capecitabine+endocrine therapy
- Placebo+endocrine therapy
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Nov 19, 2022
Breast Cancer, Breast Cancer Female Trial in China (surufatinib + fulvestrant + chidamide)
Not yet recruiting
- Breast Cancer
- Breast Cancer Female
- surufatinib + fulvestrant + chidamide
-
Anyang, China
- +4 more
Jul 18, 2022
Breast Cancer, Metastatic Cancer Trial (SHR-1316, SHR6390, Nab paclitaxel)
Not yet recruiting
- Breast Cancer
- Metastatic Cancer
- SHR-1316
- +4 more
- (no location specified)
Jan 11, 2022
Breast Cancer, Chemotherapeutic Toxicity Trial in Hanzhou (Liposomal doxorubicin + Cyclophosphamide vs Docetaxel +
Recruiting
- Breast Cancer
- Chemotherapeutic Toxicity
- Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
-
Hanzhou, Zhejing, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
Apr 7, 2022
Solid Tumor, Adult Trial (EOC202, albumin-bound paclitaxel)
Not yet recruiting
- Solid Tumor, Adult
- EOC202
- albumin-bound paclitaxel
- (no location specified)
Apr 7, 2022
Advanced Breast Cancer Trial in Beijing (Dalpiciclib in combination with endocrine therapy by Physicians choice)
Not yet recruiting
- Advanced Breast Cancer
- Dalpiciclib in combination with endocrine therapy by Physicians choice
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Jun 19, 2022
Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)
Not yet recruiting
- Metastatic Breast Cancer
- +3 more
- OP-1250
- +2 more
- (no location specified)
Aug 18, 2022
HER2-positive Breast Cancer Trial (Inavolisib, PHESGO, Endocrine therapy)
Not yet recruiting
- HER2-positive Breast Cancer
- Inavolisib
- +2 more
- (no location specified)
Mar 23, 2022
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)
Recruiting
- Metastatic Breast Cancer
- +2 more
-
Ocala, FloridaOcala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023
Patterns of Advanced Breast Cancer in Poland in Real-world Data
Recruiting
- Breast Neoplasms
-
Warsaw, PolandPfizer Polska
Jul 26, 2022
Advanced HR+ HER2 Negative Breast Carcinoma Trial in Tianjin (Enituzumab injection+Abesili tablets+Anastrozole tablets)
Recruiting
- Advanced HR+ HER2 Negative Breast Carcinoma
- Enituzumab injection+Abesili tablets+Anastrozole tablets
-
Tianjin, ChinaTianjin Cancer Hospital
Apr 6, 2022